Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients

Solid Tumor Clinical Trial

Official title:

Evaluating the Efficacy of Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors: a Phase II Prospective Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05097781
• Other study ID #: RuijinHDR
• Status: Recruiting
• Phase: Phase 2
• Start date: March 21, 2021
• Est. completion date: September 2024

Study information

• Verified date: October 2021
• Source: Ruijin Hospital
• Contact: Yujie Wang, MD
• Phone: 8602164370045
• Email: wyj12054[@]rjh.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II study to observe efficacy of combining local radiotherapy with PD-1blockade in patients with advanced solid tumors. All patients will accept at least one site of radiotherapy together with PD-1 blockade. The study will evaluate changes of unirradiated and irradiated lesions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 55
• Est. completion date: September 2024
• Est. primary completion date: June 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Adult patients 18-75 years old with the right to make medical decisions

2. Signed informed consent form

3. ECOG score of 0-2

4. Clear pathological diagnosis of the primary site

5. Multiple distant metastases

6. Stable assessment of brain metastases after treatment can be enrolled (more than 6 weeks)

7. Bone metastases combined with soft tissue mass formation can be enrolled

8. imaging with = 2 clearly assessable lesions (bone metastases alone without soft tissue mass formation, brain metastases not as target lesions)

9. expected survival = 6 months

10. Progression after = 1 prior line of therapy regimen with no standard treatment regimen or intolerable toxicities, including all three of the following:

1. Patients must have failed to respond to at least one prior standard of care regimen

2. The patient must not have a conventional treatment option that is clinically proven to provide long-term control of the disease and the patient refuses other conventional treatment options

3. The patient is intolerant to the toxic side effects of the standard treatment regimen

11. No prior immunotherapy history

12. Time to last systemic therapy (including monoclonal antibodies) = 4 weeks

13. Previous radiotherapy to non-target sites with other evaluable lesions can be enrolled

14. Laboratory examination indexes meet the following requirements: WBC = 3×109/L, ANC = 2.0×109/L, PLT = 80×109/L, Hb = 80g/L (according to the normal standards of the central laboratory department); liver function: total bilirubin, ALT and AST are = 1.5xUNL (upper limit of normal value); AST (SGOT)/ALT (SGPT) = 2.5xUNL (upper limit of normal value) ALT (SGPT) = 2.5 x IULN (upper limit of normal value); renal function: Cr?1.5xUNL (upper limit of normal value), and creatinine clearance rate?60ml/min; thyroid function T3, T4 within normal range (hypothyroidism can be supplemented with oral thyroxine); cardiac function: cardiac protein three and pro-BNP within normal range, no previous Adrenal function: normal cortisol secretion function or correctable by endocrine assessment

15. HBV infected patients with HBV-DNA copy number less than 500 IU/ml

16. No history of other malignancies within 5 years (except skin basal cell carcinoma)

Exclusion Criteria:

1. Uncontrolled brain metastases (stabilization time <6 weeks)

2. Bone metastases alone without clear soft tissue mass formation

3. Bone marrow infiltration

4. Presence of clinical factors (e.g., bleeding, active infection, or psychiatric factors) that the investigator determines may interfere with the completion of the study process

5. Inability to administer radiotherapy due to organ-threatening or other factors as assessed by the investigator

6. Patients requiring long-term maintenance steroid therapy (including oral, intravenous use); topical use or inhalation may be included in the study

7. Prior autoimmune disease or active disease [e.g., including but not limited to inflammatory bowel disease [IBD], rheumatoid arthritis, autoimmune hepatitis, systemic sclerosis (scleroderma and its variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathy (e.g., Guillain-Barre syndrome)], vitiligo and correctable endocrine deficiencies such as thyroid hypofunction, physiological cortisol hypersecretion may be included in the study and are not considered as exclusion criteria.

8. history of active tuberculosis or non-infectious pneumonia or any clinical evidence

9. Active viral hepatitis with HBV DNA > 500 IU/ml

10. Immunodeficiency syndrome

11. comorbid serious medical disorders with concomitant diseases or conditions affecting the normal enrollment of the patient or safety during the study

12. previous immunotherapy for other tumors

13. History of other malignancies within 5 years (except cured basal cell carcinoma of the skin);

14. Pregnant or lactating women;

15. Unable or unwilling to sign the informed consent form.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• PD-1 blocking antibody
All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.

Locations

Country	Name	City	State
China	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate	The proportion of patients with a tumor volume reduction of 30% lasting for at least 4 weeks,and is the sum of the proportion of complete remission (CR) and partial remission (PR)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed at least 4 weeks
Primary	non-irradiated lesion control rate(NRCR)	The percentage of non-irradiated target lesions with CR/PR or SD	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
Secondary	Progression free survival	The time from enrollment to disease progression or death from any cause	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
Secondary	Overall survival	The time from enrollment to death from any cause	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
Secondary	Rate of side effects	= grade 3 adverse effects	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months